Top Page
Qyuns Therapeutics Co., Ltd. Class H
(2509)
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 92.19M | 14.75M | -25.85M | -9.56M |
| EBITDA | -311.82M | -484.12M | -275.05M | -149.46M |
| Net Income | -335.57M | -507.75M | -346.76M | -359.48M |
Balance Sheet | ||||
| Total Assets | 983.88M | 795.58M | 1.16B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 556.55M | 377.25M | 689.57M | 758.96M |
| Total Debt | 527.60M | 346.06M | 331.49M | 355.07M |
| Total Liabilities | 762.83M | 494.63M | 419.55M | 444.45M |
| Stockholders Equity | 228.98M | 324.54M | 720.48M | 820.02M |
Cash Flow | ||||
| Free Cash Flow | -186.09M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | -25.23M | 243.11M | -11.20M | -306.69M |
| Financing Cash Flow | 351.81M | 61.21M | 263.84M | 357.63M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | 1.76B | -13.43 | 3058.51% | ― | 0.00% | 83.89% | |
56 Neutral | 1.61B | 210.48 | 4.76% | ― | 9.41% | -32.69% | |
54 Neutral | 2.06B | -3.10 | -50.52% | ― | 2.45% | 2.58% | |
53 Neutral | ― | -64.62% | ― | ― | ― | ||
53 Neutral | 1.77B | -5.97 | -38.62% | ― | -57.84% | 24.58% | |
51 Neutral | 2.67B | -2.63 | 55.21% | ― | 79.98% | -3.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Co., Ltd. has successfully completed the placement of 5,000,000 new H Shares under a general mandate, with TruMed Health Innovation Fund LP acquiring the shares at HK$20.0 each. This transaction represents approximately 2.20% of the company’s issued shares post-placement, enhancing its capital base and potentially strengthening its market position. TruMed, a Cayman Islands-based investment fund, is a significant player in healthcare equities, and its involvement may signal confidence in Qyuns Therapeutics’ future prospects.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$26.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has entered into a Placing Agreement to issue 5,000,000 new H Shares at HK$20.0 per share, representing approximately 2.25% of the company’s issued shares. The shares will be placed with TruMed Health Innovation Fund LP, a healthcare-focused investment fund. The placement is expected to raise gross proceeds of approximately HK$100.0 million, with net proceeds earmarked for strategic allocation. The transaction is conducted under a General Mandate, and no additional shareholder approval is required.
Qyuns Therapeutics Co., Ltd. reported a significant increase in revenue for the first half of 2025, reaching RMB206.49 million, primarily driven by licensing agreements and R&D services. Despite a loss of RMB30.93 million, the company showed an improvement from the previous year, with a notable decrease in adjusted loss, reflecting a positive trend in its financial performance and strategic advancements in clinical trials.
Qyuns Therapeutics Co., Ltd., a joint stock company incorporated in China, has designated Mr. Fung Che Wai, Anthony as the lead independent non-executive director to enhance corporate governance. This move aligns with the amended Corporate Governance Code effective from July 2025, aiming to improve board effectiveness and communication between directors and shareholders.
Qyuns Therapeutics Co., Ltd. has announced the advancement of its product QX004N into Phase III clinical trials, marking it as the fourth product in their pipeline to reach this stage. This milestone has triggered a payment of RMB58.0 million from Hansoh Pharma, as per their licensing agreement, which covers the research, development, manufacturing, and commercialization of QX004N in several regions including mainland China and Hong Kong. This development signifies a significant step forward in the company’s operations and strengthens its position in the pharmaceutical industry.
Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced that its board of directors will hold a meeting on August 15, 2025. The meeting will focus on approving the interim results for the first half of 2025, considering the recommendation of an interim dividend, and addressing other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting investor confidence and market positioning.
Qyuns Therapeutics Co., Ltd. has announced its decision to subscribe to two wealth management products from PDB, each with a principal amount of RMB60 million and a maturity date of October 9, 2025. This strategic move is aimed at effectively utilizing the company’s idle funds, with the products offering a principal-guaranteed floating yield and being assessed as low risk. The decision reflects Qyuns’ approach to capital management, leveraging surplus cash for potential returns while maintaining financial stability.
Qyuns Therapeutics Co., Ltd. has issued a supplemental announcement to its annual report for the year ended December 31, 2024. The announcement provides detailed information about the emoluments paid to its directors and chief executive, highlighting the compensation structure including salaries, bonuses, and share-based payments. This disclosure aims to maintain transparency with stakeholders and ensure compliance with regulatory requirements.
Qyuns Therapeutics Co., Ltd. successfully held its Annual General Meeting (AGM) on June 20, 2025, where all proposed resolutions were unanimously approved. These resolutions included the approval of the board’s report, the annual financial statements, the profit distribution plan, and the engagement of KPMG as the company’s auditor, reflecting strong shareholder support and stable governance.